Fig. 2: SARS-CoV-2 antibody titers correlate with COVID-19 disease severity.

Box and whisker plots of a Anti-N, b Anti-S, and c Anti-RBD (measured with the BioLegend anti-RBD ELISA kit) IgG titers for asymptomatic (A), mild (M), severe (S), and critical (Crt) groups at 1, 3, 6, and 12 months post-positive SARS-CoV-2 PCR. Sample sizes (n) for Anti-N are 1 month (n = 79), 3 months (n = 83), 6 months (n = 83), and 12 months (n = 66); for Anti-S are 1 month (n = 63), 3 months (n = 57), 6 months (n = 31), and 12 months (n = 11); and for Anti-RBD are 1 month (n = 75), 3 months (n = 61), 6 months (n = 37), and 12 months (n = 16). Global p-values were obtained using a cumulative link model testing the association between disease severity and antibody titers, controlling for age and sex. Pairwise comparisons were performed using the Wilcoxon test with FDR correction (* p.adj ≤ 0.05, ** p.adj ≤ 0.01, *** p.adj ≤ 0.001). Dotted lines indicate the 95% quantile of healthy controls.